Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.

IF 2.2 Q3 INFECTIOUS DISEASES

Journal of the International Association of Providers of AIDS Care Pub Date : 2024-01-01 DOI:10.1177/23259582241245223

Michael B Wohlfeiler, Laurence Brunet, Quateka Cochran, Jennifer S Fusco, Ricky K Hsu, Gregory P Fusco

{"title":"Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.","authors":"Michael B Wohlfeiler, Laurence Brunet, Quateka Cochran, Jennifer S Fusco, Ricky K Hsu, Gregory P Fusco","doi":"10.1177/23259582241245223","DOIUrl":null,"url":null,"abstract":"Background: We evaluated the impact of the CHORUS™ app on adherence to the cabotegravir and rilpivirine long-acting injectable (CAB + RPV LAI) monthly injections schedule.Methods: Healthcare centers (HCCs) were randomized to access CHORUS™ CAB + RPV LAI features (intervention) or not (control) from 01OCT2021-31JAN2022. Target window adherence (maintenance injections ≤7 days before/after target day) was assessed with multivariate logistic regression (generalized estimating equations).Results: CAB + RPV LAI was administered to 188 and 79 individuals at intervention and control HCCs, respectively. Intervention was not associated with improved target window adherence (adjusted odds ratio: 0.61 [95% CI: 0.30-1.25]). However, app use was associated with increased odds of adherence compared to no app use among all intervention HCCs (2.98 [1.26-7.06]) and at smaller HCCs (3.58 [1.31-9.80]).Conclusions: While access to CHORUS™ CAB + RPV LAI features did not improve target window adherence, app use did, especially at smaller HCCs which may not have established LAI management procedures.Trial registration: https://clinicaltrials.gov/show/NCT04863261.","PeriodicalId":17328,"journal":{"name":"Journal of the International Association of Providers of AIDS Care","volume":"23 ","pages":"23259582241245223"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11017239/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Association of Providers of AIDS Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23259582241245223","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: We evaluated the impact of the CHORUS™ app on adherence to the cabotegravir and rilpivirine long-acting injectable (CAB + RPV LAI) monthly injections schedule.

Methods: Healthcare centers (HCCs) were randomized to access CHORUS™ CAB + RPV LAI features (intervention) or not (control) from 01OCT2021-31JAN2022. Target window adherence (maintenance injections ≤7 days before/after target day) was assessed with multivariate logistic regression (generalized estimating equations).

Results: CAB + RPV LAI was administered to 188 and 79 individuals at intervention and control HCCs, respectively. Intervention was not associated with improved target window adherence (adjusted odds ratio: 0.61 [95% CI: 0.30-1.25]). However, app use was associated with increased odds of adherence compared to no app use among all intervention HCCs (2.98 [1.26-7.06]) and at smaller HCCs (3.58 [1.31-9.80]).

Conclusions: While access to CHORUS™ CAB + RPV LAI features did not improve target window adherence, app use did, especially at smaller HCCs which may not have established LAI management procedures.

Trial registration: https://clinicaltrials.gov/show/NCT04863261.

查看原文本刊更多论文

通过 CHORUS™ 应用程序和门户网站改善卡博特拉韦+利匹韦林长效注射剂目标窗口期的依从性：分组随机试验。

背景：我们评估了CHORUS™应用对卡博替拉韦和利匹韦林长效注射剂（CAB + RPV LAI）每月注射计划依从性的影响。方法：在2021年10月1日至2022年1月31日期间，医疗中心（HCCs）被随机分配使用CHORUS™ CAB + RPV LAI功能（干预）或不使用（对照）。采用多变量逻辑回归（广义估计方程）评估了目标窗口期的依从性（目标日前/后维持注射≤7天）：干预组和对照组HCC中分别有188人和79人接受了CAB+RPV LAI治疗。干预与目标窗口期依从性的改善无关（调整后的几率比：0.61 [95% CI：0.30-1.25]）。然而，与不使用应用程序相比，在所有干预HCC（2.98 [1.26-7.06] ）和较小的HCC（3.58 [1.31-9.80]）中，使用应用程序与坚持治疗的几率增加有关：虽然使用CHORUS™ CAB + RPV LAI功能并不能提高目标窗口期的依从性，但使用应用程序却能提高目标窗口期的依从性，尤其是在可能尚未建立LAI管理程序的小型HCC。试验注册：https://clinicaltrials.gov/show/NCT04863261。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊